Recombinant erythropoietin as treatment for the late hyporegenerative anemia of Rh hemolytic disease.
Infants with Rh hemolytic disease can develop a "late" anemia characterized by low serum concentrations of erythropoietin but erythroid progenitors that remain highly erythropoietin-responsive. Erythropoietin administration was evaluated in two patients as an alternative to transfusion. Reticulocyte counts increased after 5 days of treatment, and hematocrits increased after 10 days. Neither patient received erythrocyte transfusions following erythropoietin therapy.
Ohls
R K
RK
Division of Human Development and Aging, University of Utah School of Medicine, Salt Lake City.
Wirkus
P E
PE
Christensen
R D
RD
D000743:Anemia, Hemolytic / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D001856:Bone Marrow Examination; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use; D012203:Rh Isoimmunization / Q000097:blood / Q000150:complications*
D011994:Recombinant Proteins; D004921:Erythropoietin